Is Your Rare Disease on the FDA's Listening List? Many Are Not, and Comments on the New Rare Disease Framework Close December 11th

Somewhere on the FDA's website sits a list of the diseases whose patients have described their lives to the agency in a meeting or listening session held for that disease. Trial Friend checked it against the 72 conditions on this site that have no FDA-approved medicine, and 35 of them are not on it at all, among them Marfan syndrome, Fanconi anemia, moyamoya disease and 22q11.2 deletion syndrome.

Right now there is an open door for those families and every other one. On October 14, 2026 the FDA launched a Rare Disease Framework Initiative to rethink how it reviews rare disease treatments, and it is asking patients and caregivers, not only drug companies, to tell it what should change (FDA, 2026). Anyone can send a written comment until December 11, 2026, and this guide explains what the framework is, what it could and could not change for you, and how to write a comment the agency can use.

What the FDA Rare Disease Framework Is, in Plain Terms

The Rare Disease Framework Initiative is an FDA project to build a review process designed for rare disease medicines, one that judges each treatment by the evidence that can realistically be gathered for that disease, its patients and that kind of product (Federal Register, 2026). It is led by the FDA's Rare Disease Innovation Hub with the Office of the Commissioner and the 2 centers that review drugs and biologics, known as CDER and CBER, and its scope runs from a company's first meeting with the FDA through requirements that apply after approval (FDA white paper, 2026).

Small numbers sit at the center of the problem. A rare disease in US law affects fewer than 200,000 people, and some affect only a few hundred people worldwide, which makes the large placebo-controlled trials used for common diseases hard or impossible to run. Many rare diseases also have little or no natural history data, the long-term records of how a disease progresses without treatment that researchers use to judge whether a drug changed anything (FDA white paper, 2026).

“The pace of progress has not matched the scale of the need.”

FDA white paper, A New Framework for Rare Disease Review, October 2026

By the FDA's own count, about 30 million Americans, roughly 1 in 10, live with a rare disease, and as of 2025 only about 5% of recognized rare diseases had an FDA-approved treatment. About half of the novel approvals from CDER and CBER in recent years were for rare diseases, and a 2024 Government Accountability Office report counted 18 rare disease programs at the agency, most launched since 2019 (FDA white paper, 2026).

The 6 goals the FDA set for the framework

• Clearer, more consistent and more predictable rare disease decisions, explained through guidance and open communication.
• The patient voice built in early and at set points during development and review, covering disease burden, which risks are acceptable and what progress means.
• More use of outside disease experts, especially for very small populations where little is known about how the disease unfolds.
• Shared resources, training and institutional knowledge for FDA reviewers.
• Risk-based review of manufacturing and pre-approval inspections, aimed at earlier access without compromising quality, safety or effectiveness.
• New trial designs and statistical methods, backed by guidance.

The white paper does not announce a change to any pending FDA decision. It lists possible results, including revised regulations, new or revised guidance on endpoints, trial design, patient engagement and post-approval requirements, more consistency across review divisions within CDER and CBER, and training for reviewers, without setting a date for any of them (FDA white paper, 2026). The agency says it will take the time needed to get the framework right.

For families, the plainest change would be predictability. Uncertainty about how the FDA would judge rare disease evidence was the central complaint of an April 2026 coalition letter from patient groups, biotech executives and investors, and the white paper itself says every review division should tailor its expectations to the disease as a matter of course. The framework names consistency as its first goal, and the second commits the agency to building in the patient voice early and at clearly defined points in development and review.

Spinocerebellar ataxia shows what is at stake. On November 4, 2025, Biohaven announced that the FDA had declined to approve troriluzole, a daily pill for spinocerebellar ataxia, a disease with no FDA-approved treatment. According to Biohaven, the main evidence was a 3-year study comparing treated patients with untreated patients drawn from natural history studies, and the FDA cited problems that can come with that design, including potential bias, lack of pre-specification and unmeasured differences between the groups. Biohaven said the study met its prespecified main and secondary goals and that the FDA had reviewed its plan before the data were analyzed. Whether a framework built around attainable evidence would weigh a case like this differently is an open question, and as of October 21, 2026, troriluzole was no longer listed on Biohaven's pipeline page.

Safety standards stay where they are, according to the FDA. The white paper says the framework continues to adhere fully to the law's requirements of safety and effectiveness, and it describes evidence expectations fitted to each disease that must still meet the FDA's statutory standard (FDA white paper, 2026). Whether the finished framework works out that way is the open question this comment period exists to shape.

A narrower program already exists for the smallest genetic diseases. In September 2025 the FDA proposed its Rare Disease Evidence Principles, a process for treatments that correct a known genetic defect in progressive diseases affecting generally fewer than 1,000 people in the US with no adequate alternative therapy, under which 1 adequate and well-controlled study plus strong confirmatory evidence may be enough (FDA, 2025). The new framework is broader and covers rare disease review as a whole.

Has the FDA Heard From Patients With Your Rare Disease?

Of the 72 conditions on Trial Friend with no FDA-approved medicine, 29 appear on the FDA's public list of patient meetings and listening sessions, 8 are covered only by a broader meeting such as one on all inborn errors of metabolism, and 35 have no entry at all. Trial Friend matched its approved-medicine records for 235 conditions against the 256 entries on the FDA's Condition-Specific Meeting Reports page, which lists FDA-led Patient-Focused Drug Development meetings, meetings run by patient groups and FDA Patient Listening Sessions, checked October 21, 2026.

Missing from the list does not mean the FDA has never heard from those patients, since input can reach the agency in other ways and some meetings on the list still show a report as pending. What the list shows is whether a public record named for the disease exists that any reviewer can open, and for 35 conditions on this site with no approved medicine, none does. Tick-borne infections such as babesiosis and ehrlichiosis make up 8 of the 35. Alpha-gal syndrome, the meat allergy a tick bite can trigger, is counted under the 2021 food allergies meeting, which was not specific to it.

Patient groups can change their entry. The FDA invites patient organizations to plan and host their own Patient-Focused Drug Development meeting, using its FDA-led meetings as the model, and posts the reports on the same page (FDA, 2025). A comment in the framework docket is the faster route for a single family, and it does not need a group behind it.

How to Comment on the FDA Rare Disease Framework Before December 11th

Anyone can comment, including patients and caregivers, through the online form at Regulations.gov docket FDA-2026-N-12214 until 11:59 p.m. Eastern on December 11, 2026. The Federal Register notice says late comments will not be considered, and it asks commenters to name which of the FDA's 4 topics they are answering, by number:

• Topic 1: fit-for-purpose review based on the evidence that can realistically be gathered for a disease and its patients.
• Topic 2: consistency and predictability in what the FDA asks for.
• Topic 3: how the FDA works with patients, disease experts and researchers when it makes decisions.
• Topic 4: chemistry, manufacturing and controls, meaning how a medicine is made and tested, for rare disease therapies.

Families usually have the most to add on topic 3, and often on topic 1. A drug company can describe its trial design, while only a parent can say that a child walking 10 more steps matters less to them than being able to swallow safely. Benefit-risk is the FDA's term for weighing how much a treatment helps against the harm it might cause, and the framework names patient views on that balance as something it wants to hear.

A comment that helps the FDA is short and particular. One day described well tells reviewers more than a page of general frustration, and a request that names a stage of review, such as the choice of a trial's main measure, gives the agency something it can act on. If your condition is one of the 35 with no entry on the FDA's list, saying so in the comment is a fact the agency can check.

Watching the October 28th Rare Disease Framework Meeting Online

On October 28, 2026, the FDA and the Reagan-Udall Foundation will hold the Rare Disease Framework public meeting from 1 to 5 p.m. Eastern, at the FDA's White Oak campus in Silver Spring, Maryland, and on Zoom. As of October 21st, the foundation's page said requests to speak had closed and in-person seats were full, with a waitlist by email, while virtual registration remained open. People who need disability accommodations were asked to email the Rare Disease Innovation Hub by October 26, 2026 (Federal Register, 2026).

Watching first can sharpen a written comment. Hearing which points other families and companies raise shows where a comment would repeat the record and where it would add to it, and there are 6 weeks between the meeting and the deadline.

While the framework takes shape, your disease page on Trial Friend lists open clinical trials, approved medicines where they exist and any FDA decisions on the calendar, and the FDA calendar can send an alert when a decision for your condition is due.

Before You Comment, the Rare Disease Framework Questions Families Ask

The FDA started its Patient-Focused Drug Development program in 2012 to hear directly about symptoms and treatments, and its condition-specific list, which also includes patient-group meetings and listening sessions, now has 256 entries. A docket open to anyone with a rare disease lets a family be heard without waiting for a meeting of their own, and for the 35 conditions on this site with no approved medicine and no entry on that list, a comment may be the first time their experience is in the FDA's public record for this framework.